Equities

NanoViricides Inc

NanoViricides Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.58
  • Today's Change-0.08 / -4.82%
  • Shares traded121.12k
  • 1 Year change+23.44%
  • Beta0.9892
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy0
Outperform1
Hold0
Sell0
Strong Sell0

Share price forecast in USD

The one analyst offering a 12 month price target expects NanoViricides Inc share price to rise to 6.50 in the next year from the last price of 1.58.
High311.4%6.50
Med311.4%6.50
Low311.4%6.50

Earnings history & estimates in USD

On May 15, 2024, NanoViricides Inc reported 3rd quarter 2024 losses of -0.16 per share. This result exceeded the -0.19 consensus loss of the one analyst covering the company and under-performed last year's 3rd quarter results by 6.67%.
Average growth rate-2.03%
NanoViricides Inc reported annual 2022 losses of -0.70 per share on Oct 13, 2022.
Average growth rate-150.00%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.